AstraZeneca pays Hoos-helmed Scorpion $75M to take the sting out of undruggable cancer targetsnews2022-01-13T12:48:08+00:00January 13th, 2022|FierceBiotech|
JPM22, Day 3: BeiGene, Ionis promise ‘tidal wave’ of new drugs; Roche launches smart, point-of-care glucose monitornews2022-01-12T13:27:49+00:00January 12th, 2022|FierceBiotech|
JPM22, Day 3: Intellia, Editas plan to double down on gene editing data in 2022; Roche launches smart glucose monitornews2022-01-12T13:27:49+00:00January 12th, 2022|FierceBiotech|
Sanofi makes $75M preclinical bet to join Roche, Novartis and more in congested Parkinson’s fieldnews2022-01-12T13:16:49+00:00January 12th, 2022|FierceBiotech|
Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC developmentnews2022-01-12T11:09:03+00:00January 12th, 2022|FierceBiotech|
Sana links arms with IASO, Innovent in $204M biobucks pact to use CAR construct in up to 6 cell and gene therapiesnews2022-01-11T17:26:59+00:00January 11th, 2022|FierceBiotech|
Regeneron, 2seventy name the target of their first solid tumor CAR-T, aim for 2023 INDnews2022-01-11T13:14:06+00:00January 11th, 2022|FierceBiotech|
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakisnews2022-01-11T09:50:54+00:00January 11th, 2022|FierceBiotech|
JPM22, Day 2: Sage’s double-duty anxiety drug; Dexcom shows off G7 sensor data; Better late than never for Enanta in COVIDnews2022-01-11T09:50:54+00:00January 11th, 2022|FierceBiotech|
JPM 2022: Sarepta projects Duchenne muscular gene therapy will go to FDA next year, sees shares crash 15%news2022-01-10T16:50:47+00:00January 10th, 2022|FierceBiotech|
